Gaensel
Energy Group, Inc. (GEGR) acquires SSCB Swiss Stem Cells Biotech,
the only private stem cell biobank in Switzerland
SALT LAKE CITY, UT -- March 17, 2021 --
InvestorsHub NewsWire -- Gaensel Energy Group, Inc. (OTC
Pink: GEGR) Board of Directors announce today the completion of
the agreements for the acquisition of SSCB Swiss Stem Cells Biotech
SA.
The Company is pleased to announce the first of at
least 2 acquisitions in the Biotech Industry.
SSCB is a world reknown participant in Stem Cell
Technology and places Gaensel in the front of this exciting and
revolutionary health technology.
The Board expressed its pleasure working with the
President Claudio Massa where he and his advisors have worked
tirelessly over the past ninety days to ensure the success of the
negotiations and final agreements being completed. The Shareholders
of Gaensel will see the long term value this new partnership brings
to the Company.
ABOUT SSCB
SSCB Swiss Stem Cells Biotech SA is a Biotech
Company; SSCB was born in 2005 as a spin-off of Cardiocentro Ticino
of Lugano - Switzerland and is also present with other offices in
Italy, Spain, Albania and Balkan
countries.
SSCB was founded as a private bank for the
cryopreservation of human stem cells obtained from blood and cord
tissue for both autologous and allogeneic intra-family
use.
SSCB also allows the preservation of stem cells
from adipose tissue. These cells have great potential in
regenerative medicine, thanks to their ability to differentiate
into numerous cell types and thus reconstruct many compromised
tissues and organs.
SSCB operates in the field of cellular therapies
with specialization in the collection, purification,
characterization, processing and storage of stem cells for
therapeutic and aesthetic uses and for the development of new
experimental protocols.
Thanks to the constant commitment in biotechnology
in the cellular field, over the years a highly specialized know-how
and cutting-edge methods have been developed in the processes,
quality and safety of storage and release of stem
cells.
The headquarters in Vacallo, Switzerland, is a
complete and self-sufficient structure of 1,600 square meters. It
houses the bio-bank, the Laboratories for processing and
characterization of samples, Scientific Direction, Quality Control
laboratory, Quality Assurance Department, Medical Direction,
Administration and Customer Care. Through these functions it
guarantees the direct and complete management of all the phases of
the relationship with the final customer, also guaranteeing him a
unique logistic reference.
THE EXCELLENCE OF
SSCB
SSCB adheres to the strictest guidelines specific
to the field of cellular therapies and therapeutic agents. This
makes SSCB a highly specialized and cutting-edge company in the
field, able to process, store and release safe and certified
samples.
SSCB has been the first private bio-bank in Europe
to be certified since 2012 by FACT-NetCord, the specific
accreditation for cord blood banks. This accreditation places SSCB
at the same quality levels as public cord blood
bio-banks.
In 2014 SSCB obtains the validation of the
protocols for the extraction of stem cells from adipose tissue
(SVF-Stromal Vascular Fraction).
SSCB is recognized and listed in the 2019 World
Marrow Donor Association (WMDA) registry (https://share.wmda.info/display/WMDAREG/Database#)
as a private biobank capable of processing and releasing donation
samples.
In 2020, SSCB was chosen as the only private
biobank by the Swiss Federal Office of Public Health in the
Public-Private Hybrid Bank project.
SSCB receives regular inspections by SwissMedic,
Swiss Institute for Therapeutic Products, and FACT-NetCord to
process and store stem cells in their
laboratories.
SwissMedic, through their inspections of our
processes and laboratories, ensures the quality of the methods and
protocols we perform: from logistics to sample
release.
Moreover, in 2020 SSCB Laboratories have been
certified GMP, (Good Manufacturing Practices) obtaining the
qualification to produce pharmaceutical products based on stem
cells.
To support the quality and safety applied to
processing and preservation techniques, SSCB employs international
personnel highly trained and qualified in the most modern
preservation techniques applied to regenerative
therapies.
SWISS STEM CELL FOUNDATION AND FREE ADVICE
ON INTERNATIONAL CLINICAL TRIALS
The (SSCF) Swiss Stem Cell Foundation (https://sscf.ch/), is a independent and
non-profit, collaborates with SSCB and has as its goal the research
and development in the field of Stem Cells, the development of new
cell therapies in the human field based on Stem Cells, as well as
the training, consulting and dissemination of knowledge in this
field to professionals and the public.
SSCB also collaborates with prestigious
international hospitals in the treatment of patients affected by
diseases subject to clinical trials and supports parents who have
relied on the conservation of their children's stem cells. Thanks
to the collaboration with, for example, Duke University in
North Carolina and the University Hospital of Monterrey in Mexico,
SSCB has released stem cell samples successfully used for the
treatment of two separate cases of cerebral
palsy.
WHAT SSCB
DOES
Our Bio-bank has a capacity to cryopreserve a wide
range of biological materials:
•Bio-bank of Cells, Tissues and
DNA
•Cord blood stem cells
•Cord tissue stem cells
•Adipose tissue stem cells
•Peripheral Blood Conservation
•Preservation of Plasma and
Serum
•DNA storage
The cryopreservation of cells is carried out both
in liquid nitrogen and nitrogen vapors, depending on the biological
material to be stored to guarantee its highest quality and
safety
Research and
Development
•Development of stem cell extraction protocols
from different sources
•Development of tissue preservation
protocols
•Development of protocols for the preparation of
PRP, PDGF and PRGF
•Translation of search protocols into
GMP
Research Training and Development for Regenerative
Medicine
•Development of clinical protocols for the use of
stem cells
•Preparation of IMPD and documentation for the
Ethics Committee
•Partners in clinical trials using stem
cells
•Development of anti-aging
therapies
•Basic and advanced training courses to support
regenerative medicine and new application frontiers in this
field
Consulting
•Recruitment advice in international clinical
trials
•Advice in the field of personalized
medicine
Predictive
genetics
•Prenatal genetic testing
•Genetic tests on cord blood
•Anti-aging genetic testing
•Nutrigenomic genetic tests
•Microbiome test
SSCB - SWISS STEM CELLS BIOTECH
SA
Via Pizzamiglio, 12 - 6833 Vacallo -
Switzerland
Offices in: Italy, Spain, Albania, Balkan
countries
https://www.sscb-stembiotech.com/
About Gaensel Energy Group, Inc. (OTC
Pink: GEGR):
Gaensel Energy Group
asset base currently consists of proven
companies in Biotech, Commodities, Apparrel – Fashion, Green and Renewable
Energy, and Technology. The management teams for each
of these divisions are actively seeking similar partners in each
space for expansion and additional acquisitions. We have been
listed on the United States OTC Markets since 2002 and the Company
is current.
Gaensel Energy Group, Inc.
57 West 200 South
Suite 300
Salt Lake City, UT 84101
admin@gegrgroup.com
Phone: +1 518-567-3649
https://www.gegrgroup.com
Gaensel Energy (PK) (USOTC:GEGR)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Gaensel Energy (PK) (USOTC:GEGR)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
